Targeted radiation for metastatic cancer that stopped responding
Treatments studied
Part of Cancer clinical trials.
This study tests a new approach that first uses a special scan to find cancer cells that have a specific marker, then delivers targeted radiation to those cells. It is designed for people with advanced solid tumors that have spread and stopped responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to understand what the study involves.
- Your cancer must have spread to other parts of the body (metastatic), and you must have at least one tumor that can be measured on a scan.
- You must have tried at least one standard treatment that stopped working or wasn't effective.
- You need to be in reasonably good health overall, able to do light activities (score of 2 or less on a performance scale), and expected to live at least 3 more months.
- You must have a recent tumor sample (biopsy) available from your cancer, preferably from a site where it spread.
- You cannot have certain bleeding conditions, uncontrolled infections, severe heart failure, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted radioactive drug that seeks out a specific marker on lung cancer cells. It first uses a low-dose imaging scan to see if the cancer cells have this marker, then gives a higher-dose treatment to destroy those cells.
This trial tests a new imaging agent, [68Ga]Ga DOTA-5G, to see if it can better detect invasive lobular breast cancer that has spread to other parts of the body. It involves a PET/CT scan and may help doctors understand the extent of your cancer.
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
This Phase 2 trial tests whether 177Lu-DOTATATE can slow or shrink stage IV or recurrent breast cancer. It targets tumor “receptors” found on scans, using a radioactive medicine that delivers radiation directly to cancer cells.
This study tests a special PET scan called 68Ga-DOTATOC to see if it can find certain breast cancer cells in the body. It may help doctors better understand your cancer, especially if it has spread to the liver or bones.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.